Alzheimers Disease-Pipeline Review, H1 2016

Alzheimers Disease-Pipeline Review, H1 2016


  • Products Id :- GMDHC7570IDB
  • |
  • Pages: 1249
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Alzheimer's Disease-Pipeline Review, H1 2016', provides an overview of the Alzheimer's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Alzheimer's Disease

The report reviews pipeline therapeutics for Alzheimer's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Alzheimer's Disease therapeutics and enlists all their major and minor projects

The report assesses Alzheimer's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Alzheimer's Disease

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 12

Alzheimer's Disease Overview 13

Therapeutics Development 14

Alzheimer's Disease-Therapeutics under Development by Companies 16

Alzheimer's Disease-Therapeutics under Investigation by Universities/Institutes 35

Alzheimer's Disease-Pipeline Products Glance 42

Alzheimer's Disease-Products under Development by Companies 46

Alzheimer's Disease-Products under Investigation by Universities/Institutes 73

Alzheimer's Disease-Companies Involved in Therapeutics Development 83

Alzheimer's Disease-Therapeutics Assessment 287

Drug Profiles 343

Alzheimer's Disease-Recent Pipeline Updates 1005

Alzheimer's Disease-Dormant Projects 1130

Alzheimer's Disease-Discontinued Products 1172

Alzheimer's Disease-Product Development Milestones 1183

Appendix 1191

List of Figures

Number of Products under Development for Alzheimer's Disease, H1 2016 71

Number of Products under Development for Alzheimer's Disease-Comparative Analysis, H1 2016 72

Number of Products under Development by Companies, H1 2016 73

Number of Products under Investigation by Universities/Institutes, H1 2016 92

Comparative Analysis by Late Stage Development, H1 2016 99

Comparative Analysis by Clinical Stage Development, H1 2016 100

Comparative Analysis by Early Stage Products, H1 2016 101

Assessment by Monotherapy Products, H1 2016 344

Assessment by Combination Products, H1 2016 345

Number of Products by Top 10 Targets, H1 2016 346

Number of Products by Stage and Top 10 Targets, H1 2016 346

Number of Products by Top 10 Mechanism of Actions, H1 2016 377

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 377

Number of Products by Top 10 Routes of Administration, H1 2016 396

Number of Products by Stage and Top 10 Routes of Administration, H1 2016 396

Number of Products by Top 10 Molecule Types, H1 2016 398

Number of Products by Stage and Top 10 Molecule Types, H1 2016 398

List of Tables

Number of Products under Development for Alzheimer's Disease, H1 2016 71

Number of Products under Development for Alzheimer's Disease-Comparative Analysis, H1 2016 72

Number of Products under Development by Companies, H1 2016 74

Number of Products under Development by Companies, H1 2016 (Contd..1) 75

Number of Products under Development by Companies, H1 2016 (Contd..2) 76

Number of Products under Development by Companies, H1 2016 (Contd..3) 77

Number of Products under Development by Companies, H1 2016 (Contd..4) 78

Number of Products under Development by Companies, H1 2016 (Contd..5) 79

Number of Products under Development by Companies, H1 2016 (Contd..6) 80

Number of Products under Development by Companies, H1 2016 (Contd..7) 81

Number of Products under Development by Companies, H1 2016 (Contd..8) 82

Number of Products under Development by Companies, H1 2016 (Contd..9) 83

Number of Products under Development by Companies, H1 2016 (Contd..10) 84

Number of Products under Development by Companies, H1 2016 (Contd..11) 85

Number of Products under Development by Companies, H1 2016 (Contd..12) 86

Number of Products under Development by Companies, H1 2016 (Contd..13) 87

Number of Products under Development by Companies, H1 2016 (Contd..14) 88

Number of Products under Development by Companies, H1 2016 (Contd..15) 89

Number of Products under Development by Companies, H1 2016 (Contd..16) 90

Number of Products under Development by Companies, H1 2016 (Contd..17) 91

Number of Products under Investigation by Universities/Institutes, H1 2016 92

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 93

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 94

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 95

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 96

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 97

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..6) 98

Comparative Analysis by Late Stage Development, H1 2016 99

Comparative Analysis by Clinical Stage Development, H1 2016 100

Comparative Analysis by Early Stage Development, H1 2016 101

Comparative Analysis by Unknown Stage Development, H1 2016 102

Products under Development by Companies, H1 2016 103

Products under Development by Companies, H1 2016 (Contd..1) 104

Products under Development by Companies, H1 2016 (Contd..2) 105

Products under Development by Companies, H1 2016 (Contd..3) 106

Products under Development by Companies, H1 2016 (Contd..4) 107

Products under Development by Companies, H1 2016 (Contd..5) 108

Products under Development by Companies, H1 2016 (Contd..6) 109

Products under Development by Companies, H1 2016 (Contd..7) 110

Products under Development by Companies, H1 2016 (Contd..8) 111

Products under Development by Companies, H1 2016 (Contd..9) 112

Products under Development by Companies, H1 2016 (Contd..10) 113

Products under Development by Companies, H1 2016 (Contd..11) 114

Products under Development by Companies, H1 2016 (Contd..12) 115

Products under Development by Companies, H1 2016 (Contd..13) 116

Products under Development by Companies, H1 2016 (Contd..14) 117

Products under Development by Companies, H1 2016 (Contd..15) 118

Products under Development by Companies, H1 2016 (Contd..16) 119

Products under Development by Companies, H1 2016 (Contd..17) 120

Products under Development by Companies, H1 2016 (Contd..18) 121

Products under Development by Companies, H1 2016 (Contd..19) 122

Products under Development by Companies, H1 2016 (Contd..20) 123

Products under Development by Companies, H1 2016 (Contd..21) 124

Products under Development by Companies, H1 2016 (Contd..22) 125

Products under Development by Companies, H1 2016 (Contd..23) 126

Products under Development by Companies, H1 2016 (Contd..24) 127

Products under Development by Companies, H1 2016 (Contd..25) 128

Products under Development by Companies, H1 2016 (Contd..26) 129

Products under Investigation by Universities/Institutes, H1 2016 130

Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 131

Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 132

Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 133

Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 134

Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 135

Products under Investigation by Universities/Institutes, H1 2016 (Contd..6) 136

Products under Investigation by Universities/Institutes, H1 2016 (Contd..7) 137

Products under Investigation by Universities/Institutes, H1 2016 (Contd..8) 138

Products under Investigation by Universities/Institutes, H1 2016 (Contd..9) 139

Alzheimer's Disease-Pipeline by AB Science SA, H1 2016 140

Alzheimer's Disease-Pipeline by AbbVie Inc., H1 2016 141

Alzheimer's Disease-Pipeline by AC Immune SA, H1 2016 142

Alzheimer's Disease-Pipeline by Accera, Inc., H1 2016 143

Alzheimer's Disease-Pipeline by Acelot, Inc., H1 2016 144

Alzheimer's Disease-Pipeline by Actinogen Limited, H1 2016 145

Alzheimer's Disease-Pipeline by Acumen Pharmaceuticals, Inc., H1 2016 146

Alzheimer's Disease-Pipeline by Addex Therapeutics Ltd, H1 2016 147

Alzheimer's Disease-Pipeline by Affibody AB, H1 2016 148

Alzheimer's Disease-Pipeline by AFFiRiS AG, H1 2016 149

Alzheimer's Disease-Pipeline by Alector LLC, H1 2016 150

Alzheimer's Disease-Pipeline by Alkermes Plc, H1 2016 151

Alzheimer's Disease-Pipeline by ALSP, Inc., H1 2016 152

Alzheimer's Disease-Pipeline by Alzhyme Pty Ltd, H1 2016 153

Alzheimer's Disease-Pipeline by Alzinova AB, H1 2016 154

Alzheimer's Disease-Pipeline by AlzProtect SAS, H1 2016 155

Alzheimer's Disease-Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 156

Alzheimer's Disease-Pipeline by Amgen Inc., H1 2016 157

Alzheimer's Disease-Pipeline by Anavex Life Sciences Corp., H1 2016 158

Alzheimer's Disease-Pipeline by Aphios Corporation, H1 2016 159

Alzheimer's Disease-Pipeline by Apodemus AB, H1 2016 160

Alzheimer's Disease-Pipeline by Applied Research using OMIC Sciences, S.L., H1 2016 161

Alzheimer's Disease-Pipeline by Araclon Biotech, S.L., H1 2016 162

Alzheimer's Disease-Pipeline by Archer Pharmaceuticals, Inc., H1 2016 163

Alzheimer's Disease-Pipeline by ArmaGen Inc., H1 2016 164

Alzheimer's Disease-Pipeline by Artery Therapeutics, Inc., H1 2016 165

Alzheimer's Disease-Pipeline by AskAt Inc., H1 2016 166

Alzheimer's Disease-Pipeline by Astellas Pharma Inc., H1 2016 167

Alzheimer's Disease-Pipeline by AstraZeneca Plc, H1 2016 168

Alzheimer's Disease-Pipeline by Asubio Pharma Co., Ltd., H1 2016 169

Alzheimer's Disease-Pipeline by Ausio Pharmaceuticals, LLC, H1 2016 170

Alzheimer's Disease-Pipeline by Avineuro Pharmaceuticals, Inc., H1 2016 171

Alzheimer's Disease-Pipeline by Axerion Therapeutics, Inc., H1 2016 172

Alzheimer's Disease-Pipeline by Axon Neuroscience SE, H1 2016 173

Alzheimer's Disease-Pipeline by Axovant Sciences Ltd., H1 2016 174

Alzheimer's Disease-Pipeline by Axsome Therapeutics, Inc., H1 2016 175

Alzheimer's Disease-Pipeline by Axxam SpA, H1 2016 176

Alzheimer's Disease-Pipeline by Beactica AB, H1 2016 177

Alzheimer's Disease-Pipeline by Berg LLC, H1 2016 178

Alzheimer's Disease-Pipeline by BioArctic Neuroscience AB, H1 2016 179

Alzheimer's Disease-Pipeline by Bioasis Technologies Inc., H1 2016 180

Alzheimer's Disease-Pipeline by Biogen, Inc., H1 2016 181

Alzheimer's Disease-Pipeline by Biomar Microbial Technologies, H1 2016 182

Alzheimer's Disease-Pipeline by Bionature E.A. Ltd., H1 2016 183

Alzheimer's Disease-Pipeline by Boehringer Ingelheim GmbH, H1 2016 184

Alzheimer's Disease-Pipeline by Bristol-Myers Squibb Company, H1 2016 185

Alzheimer's Disease-Pipeline by Bsim2, H1 2016 186

Alzheimer's Disease-Pipeline by Cardax Pharmaceuticals, Inc., H1 2016 187

Alzheimer's Disease-Pipeline by Celon Pharma Sp. z o.o., H1 2016 188

Alzheimer's Disease-Pipeline by CHA Bio & Diostech Co., Ltd., H1 2016 189

Alzheimer's Disease-Pipeline by Chase Pharmaceuticals Corporation, H1 2016 190

Alzheimer's Disease-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 191

Alzheimer's Disease-Pipeline by Clera Inc., H1 2016 192

Alzheimer's Disease-Pipeline by Cognition Therapeutics, Inc., H1 2016 193

Alzheimer's Disease-Pipeline by Cognosci, Inc., H1 2016 194

Alzheimer's Disease-Pipeline by CohBar, Inc., H1 2016 195

Alzheimer's Disease-Pipeline by CoLucid Pharmaceuticals, Inc., H1 2016 196

Alzheimer's Disease-Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016 197

Alzheimer's Disease-Pipeline by Corium International, Inc., H1 2016 198

Alzheimer's Disease-Pipeline by Coronis Partners Ltd., H1 2016 199

Alzheimer's Disease-Pipeline by Critical Outcome Technologies Inc., H1 2016 200

Alzheimer's Disease-Pipeline by Crossbeta Biosciences B.V., H1 2016 201

Alzheimer's Disease-Pipeline by D-Pharm Ltd., H1 2016 202

Alzheimer's Disease-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016 203

Alzheimer's Disease-Pipeline by Daval International Limited, H1 2016 204

Alzheimer's Disease-Pipeline by DermaXon, LLC, H1 2016 205

Alzheimer's Disease-Pipeline by Domain Therapeutics SA, H1 2016 206

Alzheimer's Disease-Pipeline by Eisai Co., Ltd., H1 2016 207

Alzheimer's Disease-Pipeline by Eli Lilly and Company, H1 2016 208

Alzheimer's Disease-Pipeline by EncephRx, Inc., H1 2016 209

Alzheimer's Disease-Pipeline by ENKAM Pharmaceuticals A/S, H1 2016 210

Alzheimer's Disease-Pipeline by Ensemble Therapeutics Corporation, H1 2016 211

Alzheimer's Disease-Pipeline by Ensol Biosciences Inc., H1 2016 212

Alzheimer's Disease-Pipeline by Epigen Biosciences, Inc., H1 2016 213

Alzheimer's Disease-Pipeline by Euroscreen S.A., H1 2016 214

Alzheimer's Disease-Pipeline by Evotec AG, H1 2016 215

Alzheimer's Disease-Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 216

Alzheimer's Disease-Pipeline by FORUM Pharmaceuticals Inc., H1 2016 217

Alzheimer's Disease-Pipeline by Genentech, Inc., H1 2016 218

Alzheimer's Disease-Pipeline by Genervon Biopharmaceuticals, LLC, H1 2016 219

Alzheimer's Disease-Pipeline by GlaxoSmithKline Plc, H1 2016 220

Alzheimer's Disease-Pipeline by GliaCure Inc., H1 2016 221

Alzheimer's Disease-Pipeline by Golden Biotechnology Corp., H1 2016 222

Alzheimer's Disease-Pipeline by Grifols, S.A., H1 2016 223

Alzheimer's Disease-Pipeline by H. Lundbeck A/S, H1 2016 224

Alzheimer's Disease-Pipeline by Heptares Therapeutics Limited, H1 2016 225

Alzheimer's Disease-Pipeline by Herantis Pharma Plc, H1 2016 226

Alzheimer's Disease-Pipeline by Humanetics Corporation, H1 2016 227

Alzheimer's Disease-Pipeline by Ichor Medical Systems, Inc., H1 2016 228

Alzheimer's Disease-Pipeline by Icure Pharmaceutical Inc., H1 2016 229

Alzheimer's Disease-Pipeline by Immungenetics AG, H1 2016 230

Alzheimer's Disease-Pipeline by Immunome Inc., H1 2016 231

Alzheimer's Disease-Pipeline by Impel NeuroPharma, Inc., H1 2016 232

Alzheimer's Disease-Pipeline by ImStar Therapeutics Inc., H1 2016 233

Alzheimer's Disease-Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 234

Alzheimer's Disease-Pipeline by IntelGenx Corp., H1 2016 235

Alzheimer's Disease-Pipeline by Intellect Neurosciences, Inc., H1 2016 236

Alzheimer's Disease-Pipeline by Intra-Cellular Therapies, Inc., H1 2016 237

Alzheimer's Disease-Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 238

Alzheimer's Disease-Pipeline by Io Therapeutics, Inc., H1 2016 239

Alzheimer's Disease-Pipeline by Iproteos S.L., H1 2016 240

Alzheimer's Disease-Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016 241

Alzheimer's Disease-Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016 242

Alzheimer's Disease-Pipeline by Johnson & Johnson, H1 2016 243

Alzheimer's Disease-Pipeline by K-Stemcell Co., Ltd., H1 2016 244

Alzheimer's Disease-Pipeline by Kadmon Corporation, LLC, H1 2016 245

Alzheimer's Disease-Pipeline by Kalgene Pharmaceuticals Inc., H1 2016 246

Alzheimer's Disease-Pipeline by Kareus Therapeutics, SA, H1 2016 247

Alzheimer's Disease-Pipeline by KineMed, Inc., H1 2016 248

Alzheimer's Disease-Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 249

Alzheimer's Disease-Pipeline by Lead Discovery Center GmbH, H1 2016 250

Alzheimer's Disease-Pipeline by Les Laboratoires Servier SAS, H1 2016 251

Alzheimer's Disease-Pipeline by Lipopharma Therapeutics SL, H1 2016 252

Alzheimer's Disease-Pipeline by Living Cell Technologies Limited, H1 2016 253

Alzheimer's Disease-Pipeline by Lupin Limited, H1 2016 254

Alzheimer's Disease-Pipeline by M3 Biotechnology, Inc., H1 2016 255

Alzheimer's Disease-Pipeline by ManRos Therapeutics, H1 2016 256

Alzheimer's Disease-Pipeline by MedDay, H1 2016 257

Alzheimer's Disease-Pipeline by Medestea Research & Production S.p.A., H1 2016 258

Alzheimer's Disease-Pipeline by MedImmune, LLC, H1 2016 259

Alzheimer's Disease-Pipeline by Medisyn Technologies, Inc., H1 2016 260

Alzheimer's Disease-Pipeline by Merck & Co., Inc., H1 2016 261

Alzheimer's Disease-Pipeline by Merz Pharma GmbH & Co. KgaA, H1 2016 262

Alzheimer's Disease-Pipeline by Metabolic Solutions Development Company, LLC, H1 2016 263

Alzheimer's Disease-Pipeline by Mithridion, Inc., H1 2016 264

Alzheimer's Disease-Pipeline by NAL Pharmaceuticals Ltd., H1 2016 265

Alzheimer's Disease-Pipeline by Nanomerics Ltd, H1 2016 266

Alzheimer's Disease-Pipeline by Nanotherapeutics, Inc., H1 2016 267

Alzheimer's Disease-Pipeline by Neuralstem, Inc., H1 2016 268

Alzheimer's Disease-Pipeline by Neuraltus Pharmaceuticals, Inc., H1 2016 269

Alzheimer's Disease-Pipeline by Neurim Pharmaceuticals Ltd, H1 2016 270

Alzheimer's Disease-Pipeline by Neurodyn Inc., H1 2016 271

Alzheimer's Disease-Pipeline by NeuroGeneration, Inc., H1 2016 272

Alzheimer's Disease-Pipeline by NeuroGenetic Pharmaceuticals, Inc., H1 2016 273

Alzheimer's Disease-Pipeline by NeuroNascent, Inc., H1 2016 274

Alzheimer's Disease-Pipeline by Neuronax SAS, H1 2016 275

Alzheimer's Disease-Pipeline by NeurOp, Inc, H1 2016 276

Alzheimer's Disease-Pipeline by NeuroPhage Pharmaceuticals, Inc., H1 2016 277

Alzheimer's Disease-Pipeline by Neuropore Therapies, Inc., H1 2016 278

Alzheimer's Disease-Pipeline by Neurotez, Inc., H1 2016 279

Alzheimer's Disease-Pipeline by New World Laboratories, Inc., H1 2016 280

Alzheimer's Disease-Pipeline by nLife Therapeutics, S.L., H1 2016 281

Alzheimer's Disease-Pipeline by NLS Pharma Group, H1 2016 282

Alzheimer's Disease-Pipeline by Novartis AG, H1 2016 283

Alzheimer's Disease-Pipeline by Oligomerix, inc., H1 2016 284

Alzheimer's Disease-Pipeline by Oryzon Genomics S.A., H1 2016 285

Alzheimer's Disease-Pipeline by P2D Bioscience, H1 2016 286

Alzheimer's Disease-Pipeline by Pain Therapeutics, Inc., H1 2016 287

Alzheimer's Disease-Pipeline by Palumed S.A., H1 2016 288

Alzheimer's Disease-Pipeline by Panacea Pharmaceuticals, Inc., H1 2016 289

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AB Science SA

AbbVie Inc.

AC Immune SA

Accera, Inc.

Acelot, Inc.

Actinogen Limited

Acumen Pharmaceuticals, Inc.

Addex Therapeutics Ltd

Affibody AB

AFFiRiS AG

Alector LLC

Alkermes Plc

ALSP, Inc.

Alzhyme Pty Ltd

Alzinova AB

AlzProtect SAS

Amarantus Bioscience Holdings, Inc.

Amgen Inc.

Anavex Life Sciences Corp.

Aphios Corporation

Apodemus AB

Applied Research using OMIC Sciences, S.L.

Araclon Biotech, S.L.

Archer Pharmaceuticals, Inc.

ArmaGen Inc.

Artery Therapeutics, Inc.

AskAt Inc.

Astellas Pharma Inc.

AstraZeneca Plc

Asubio Pharma Co., Ltd.

Ausio Pharmaceuticals, LLC

Avineuro Pharmaceuticals, Inc.

Axerion Therapeutics, Inc.

Axon Neuroscience SE

Axovant Sciences Ltd.

Axsome Therapeutics, Inc.

Axxam SpA

Beactica AB

Berg LLC

BioArctic Neuroscience AB

Bioasis Technologies Inc.

Biogen, Inc.

Biomar Microbial Technologies

Bionature E.A. Ltd.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Bsim2

Cardax Pharmaceuticals, Inc.

Celon Pharma Sp. z o.o.

CHA Bio & Diostech Co., Ltd.

Chase Pharmaceuticals Corporation

Chong Kun Dang Pharmaceutical Corp.

Clera Inc.

Cognition Therapeutics, Inc.

Cognosci, Inc.

CohBar, Inc.

CoLucid Pharmaceuticals, Inc.

Connexios Life Sciences Pvt. Ltd.

Corium International, Inc.

Coronis Partners Ltd.

Critical Outcome Technologies Inc.

Crossbeta Biosciences B.V.

D-Pharm Ltd.

Daewoong Pharmaceutical Co., Ltd.

Daval International Limited

DermaXon, LLC

Domain Therapeutics SA

Eisai Co., Ltd.

Eli Lilly and Company

EncephRx, Inc.

ENKAM Pharmaceuticals A/S

Ensemble Therapeutics Corporation

Ensol Biosciences Inc.

Epigen Biosciences, Inc.

Euroscreen S.A.

Evotec AG

F. Hoffmann-La Roche Ltd.

FORUM Pharmaceuticals Inc.

Genentech, Inc.

Genervon Biopharmaceuticals, LLC

GlaxoSmithKline Plc

GliaCure Inc.

Golden Biotechnology Corp.

Grifols, S.A.

H. Lundbeck A/S

Heptares Therapeutics Limited

Herantis Pharma Plc

Humanetics Corporation

Ichor Medical Systems, Inc.

Icure Pharmaceutical Inc.

Immungenetics AG

Immunome Inc.

Impel NeuroPharma, Inc.

ImStar Therapeutics Inc.

Inovio Pharmaceuticals, Inc.

IntelGenx Corp.

Intellect Neurosciences, Inc.

Intra-Cellular Therapies, Inc.

INVENT Pharmaceuticals, Inc.

Io Therapeutics, Inc.

Iproteos S.L.

Jeil Pharmaceutical Co., Ltd.

Jiangsu Kanion Pharmaceutical Co., Ltd.

Johnson & Johnson

K-Stemcell Co., Ltd.

Kadmon Corporation, LLC

Kalgene Pharmaceuticals Inc.

Kareus Therapeutics, SA

KineMed, Inc.

Kyowa Hakko Kirin Co., Ltd.

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

Lipopharma Therapeutics SL

Living Cell Technologies Limited

Lupin Limited

M3 Biotechnology, Inc.

ManRos Therapeutics

MedDay

Medestea Research & Production S.p.A.

MedImmune, LLC

Medisyn Technologies, Inc.

Merck & Co., Inc.

Merz Pharma GmbH & Co. KgaA

Metabolic Solutions Development Company, LLC

Mithridion, Inc.

NAL Pharmaceuticals Ltd.

Nanomerics Ltd

Nanotherapeutics, Inc.

Neuralstem, Inc.

Neuraltus Pharmaceuticals, Inc.

Neurim Pharmaceuticals Ltd

Neurodyn Inc.

NeuroGeneration, Inc.

NeuroGenetic Pharmaceuticals, Inc.

NeuroNascent, Inc.

Neuronax SAS

NeurOp, Inc

NeuroPhage Pharmaceuticals, Inc.

Neuropore Therapies, Inc.

Neurotez, Inc.

New World Laboratories, Inc.

nLife Therapeutics, S.L.

NLS Pharma Group

Novartis AG

Oligomerix, inc.

Oryzon Genomics S.A.

P2D Bioscience

Pain Therapeutics, Inc.

Palumed S.A.

Panacea Pharmaceuticals, Inc.

PeptiDream Inc.

Peptron, Inc.

Pfizer Inc.

PharmaKure Limited

PharmatrophiX, Inc.

Pharmaxis Limited

Pharnext SAS

Pivot Pharmaceuticals Inc

Plexxikon Inc.

Prana Biotechnology Limited

Probiodrug AG

Progenra, Inc.

Proteome Sciences Plc

Proteostasis Therapeutics, Inc.

Prothena Corporation Plc

QR Pharma, Inc.

Radius Health, Inc.

Regenera Pharma Ltd.

reMYND NV

Resverlogix Corp.

Sage Therapeutics, Inc.

SanBio, Inc.

Saneron CCEL Therapeutics, Inc.

Saniona AB

Sanofi

SeneXta Therapeutics SA

Serometrix, LLC

SignPath Pharma Inc

Simcere Pharmaceutical Group

SK Biopharmaceuticals Co., Ltd.

SOM Innovation Biotech SL

Spectrum Pharmaceuticals, Inc.

Stemedica Cell Technologies, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Summit Therapeutics Plc

Suven Life Sciences Ltd.

Takeda Pharmaceutical Company Limited

TauRx Therapeutics Ltd.

TechnologieAllianz e. V.

TechnoPhage SA

Tetra Discovery Partners LLC

Therapix Biosciences Ltd

Toyama Chemical Co., Ltd.

Transition Therapeutics Inc.

Treventis Corporation

TyrNovo Ltd.

UCB S.A.

Varinel, Inc.

Virobay Inc.

Vitae Pharmaceuticals, Inc.

Vivus, Inc.

vTv Therapeutics LLC

Vybion, Inc.

Wellstat Therapeutics Corporation

Alzheimer's Disease Therapeutic Products under Development, Key Players in Alzheimer's Disease Therapeutics, Alzheimer's Disease Pipeline Overview, Alzheimer's Disease Pipeline, Alzheimer's Disease Pipeline Assessment

select a license

Single User License
USD 2500 INR 160900
Site License
USD 5000 INR 321800
Corporate User License
USD 7500 INR 482700

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com